T. Rowe Price Associates
KMTS

T. Rowe Price Associates’s Kestra Medical Technologies KMTS Stock Holding History

T. Rowe Price Associates’s Portfolio KMTS Stock Details KMTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$119M Buy
5,968,664
+1,599,235
+37% +$37.7M 0.01% 581
2025
Q4 		$116M Buy
4,369,429
+2,529,851
+138% +$65.2M 0.01% 600
2025
Q3 		$43.7M Buy
1,839,578
+842,382
+84% +$15.1M ﹤0.01% 845
2025
Q2 		$16.5M Buy
997,196
+147,778
+17% +$3.23M ﹤0.01% 1000
2025
Q1 		$21.2M Buy
+849,418
New +$19.5M ﹤0.01% 940

Other funds holding KMTS

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
YF
Yu Fan $97M AUM 57.2% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates's KMTS Position: Q1 2026 in Review

T. Rowe Price Associates increased its Kestra Medical Technologies (KMTS) stake by 37% in Q1 2026, buying an estimated $37.7M and bringing the position to 5,968,664 shares worth $119M. The position accounts for 0.01% of the portfolio, ranked #581.

T. Rowe Price Associates first reported a position in KMTS in Q1 2025 and has held it in 5 quarters since. 103 funds tracked by Wall St. Rank hold KMTS as of Q1 2026.

  • T. Rowe Price Associates held 5,968,664 shares of Kestra Medical Technologies worth $119M as of Q1 2026.
  • T. Rowe Price Associates bought 1,599,235 Kestra Medical Technologies shares in Q1 2026, an estimated $37.7M.
  • Kestra Medical Technologies made up 0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #581 holding.
  • T. Rowe Price Associates first reported a position in Kestra Medical Technologies in Q1 2025 and has held it in 5 quarters since.
  • 103 funds tracked by Wall St. Rank held Kestra Medical Technologies as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.